Jianxiang Wang
Chinese Academy of Medical Sciences · Institute of Institute of Hematology & Blood Diseases Hospital · The Haematology Hospital of the Chinese Academy of Medical Sciences
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Jianxiang Wang as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 08:12 UTC. Open this list on ClinicalTrials.gov
- Ph3NCT07925190 · A Phase III Study Comparing Mesutoclax + Azacitidine Versus Venetoclax + Azacitidine in Untreated Acute Myeloid Leukemia (AML) PatientsBeijing InnoCare Pharma Tech Co., Ltd. · not yet recruiting · Acute Myeloblastic Leukaemia · principal investigator
- Ph2NCT07743112 · A Phase 2 Study of MAX-40279 Combined With Venetoclax and Azacitidine in Unfit Newly Diagnosed Acute Myeloid LeukemiaMaxinovel Pty., Ltd. · recruiting · Acute Myeloid Leukemia · principal investigator
- Ph1NCT07347171 · A Phase 1 Study of CG009301 for Injection in Adult Subjects With Recurrent or Refractory Haematological MalignanciesCullgen (Shanghai),Inc · recruiting · Leukemia, AML, MDS · principal investigator
- Ph1NCT07169487 · Adjunctive Methylene Blue for Immunotherapy-related CRS and ICANS: Phase I StudyInstitute of Hematology & Blood Diseases Hospital, China · recruiting · Cytokine Release Syndrome, ICANS · principal investigator
- Ph1/Ph2NCT07153068 · SupCD7 CART for Relapsed or Refractory CD7 Positive Hematologic MalignanciesInstitute of Hematology & Blood Diseases Hospital, China · recruiting · T Lymphoblastic Leukemia/Lymphoma, Acute Myeloid Leukemia (AML) · principal investigator
- Ph1NCT07137637 · HPB-092 for the Treatment of Relapsed and Refractory Acute Myeloid LeukemiaHangzhou Polymed Biopharmaceuticals, Inc. · recruiting · Relapsed and Refractory Acute Myeloid Leukemia (RR-AML) · principal investigator
- Ph1NCT07109518 · uCD7 CART for Relapsed or Refractory CD7 Positive Hematologic MalignanciesInstitute of Hematology & Blood Diseases Hospital, China · recruiting · Acute Myeloid Leukemia (AML), T Lymphoblastic Leukemia/Lymphoma · principal investigator
- N/ANCT06481228 · Efficacy and Safety of TKI Combined With Chemotherapy and Sequential CAR-T Cells in ND Adult Patients With Ph+ ALLInstitute of Hematology & Blood Diseases Hospital, China · recruiting · Philadelphia Positive Acute Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia, Adult · principal investigator
- N/ANCT06481241 · Efficacy and Safety of Chemotherapy Combined With CAR-T Cells in Newly Diagnosed Adult Patients With Ph- B-ALLInstitute of Hematology & Blood Diseases Hospital, China · recruiting · Philadelphia Chromosome Negative ALL, Acute Lymphoblastic Leukemia, Adult · principal investigator
- N/ANCT06461351 · Long-term Observational Study of Patients Treated With Inaticabtagene Autoleucel InjectionJuventas Cell Therapy Ltd. · recruiting · B-cell Tumors · principal investigator
- N/ANCT06450067 · Inaticabtagene Autoleucel Injection Treatment for Adult Relapsed or Refractory Acute Lymphocytic LeukemiaJuventas Cell Therapy Ltd. · recruiting · B-cell Acute Lymphoblastic Leukemia · principal investigator
- Ph3NCT06389292 · A Pivotal Study of APG-2575 (Lisaftoclax) Combined With Azacitidine in the Treatment of Acute Myeloid LeukemiaAscentage Pharma Group Inc. · recruiting · Acute Myeloid Leukemia · principal investigator
- Ph2NCT06387121 · Efficacy and Safety of Low-dose Chemotherapy Plus Immuno-targeted Drugs in Newly Diagnosed Adult Ph- B-ALLInstitute of Hematology & Blood Diseases Hospital, China · recruiting · Precursor Cell Lymphoblastic Leukemia-Lymphoma · principal investigator
- Ph1NCT06387082 · A Clinical Study of HMPL-506 in Patients With Hematological MalignanciesHutchmed · recruiting · Hematological Malignancies · principal investigator
- N/ANCT06386302 · Chidamide, Venetoclax, and Azacitidine for Newly Diagnosed Acute Myeloid LeukemiaInstitute of Hematology & Blood Diseases Hospital, China · recruiting · AML, Acute Myeloid Leukemia · principal investigator
- Ph1/Ph2NCT06206174 · TGRX-814 Chinese Phase I/II in Patients With Hematological MalignanciesShenzhen TargetRx Co., Ltd. · recruiting · Hematologic Malignancy, Non Hodgkin Lymphoma, Acute Myeloid Leukemia · principal investigator
- Ph1/Ph2NCT06009107 · A Study of HY004 Treatment in Adult Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (r/r B-ALL)Juventas Cell Therapy Ltd. · withdrawn · B-cell Acute Lymphoblastic Leukemia · principal investigator
- Ph1NCT05924750 · A Study of BL-M11D1 in Patients With Relapsed/Refractory Acute Myeloid LeukemiaSichuan Baili Pharmaceutical Co., Ltd. · recruiting · Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) · principal investigator
- N/ANCT05801835 · A Bioequivalence Study of (Cytarabine: Daunorubicin) Liposome for InjectionCSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. · unknown · Acute Myeloid Leukemia · principal investigator
- N/ANCT05739409 · LILRB4 STAR-T Cell Therapy for Monocytic LeukemiaInstitute of Hematology & Blood Diseases Hospital, China · completed · Acute Myelogenous Leukemia, Chronic Myelomonocytic Leukemia · principal investigator
- Ph2NCT05660473 · Pediatric-inspired Regimen Combined With Venetoclax for Adolescent and Adult Patients With de Novo Philadelphia Chromosome-Negative Acute Lymphoblastic LeukemiaInstitute of Hematology & Blood Diseases Hospital, China · recruiting · Precursor Cell Lymphoblastic Leukemia-Lymphoma · principal investigator
- Ph2NCT05594784 · Olverembatinib Combined With Reduced-Intensity Chemotherapy and Venetoclax for de Novo Ph+ ALLInstitute of Hematology & Blood Diseases Hospital, China · completed · Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia · principal investigator
- Ph1/Ph2NCT05579132 · A Clinical Study of MK-1045 (CN201) in People With Precursor B-cell Acute Lymphoblastic Leukemia (MK-1045-002)MSD R&D (China) Co., Ltd. · recruiting · Acute Lymphoblastic Leukemia · principal investigator
- Ph1NCT05320809 · Study of 3D189 in Patients With Hematologic Malignancies3D Medicines · completed · Acute Leukemia, Multiple Myeloma, Non-Hodgkin Lymphoma · principal investigator
- Ph3NCT05054543 · Study to Evaluate the Efficacy of Uproleselan in Combination With Chemotherapy in Chinese Patients With R/R AMLApollomics Inc. · terminated · Relapsed/Refractory AML · principal investigator
- Ph1NCT04839341 · Study to Evaluate PK and Safety With Uproleselan Combined With Chemotherapy to Treat Chinese R/R AML PatientsApollomics Inc. · completed · Relapsed/Refractory AML · principal investigator
- Ph2NCT04684147 · Clinical Trial of CNCT19 Cell Injection in the Treatment of Relapsed or Refractory Acute Lymphoblastic LeukemiaJuventas Cell Therapy Ltd. · recruiting · Relapsed or Refractory Acute Lymphoblastic Leukemia · principal investigator
- Ph1NCT04606433 · Phase I Clinical Study of GNC-038 in Patients With Non-Hodgkin's Lymphoma or Acute Lymphoblastic LeukemiaSichuan Baili Pharmaceutical Co., Ltd. · active not recruiting · Non Hodgkin Lymphoma, Acute Lymphoblastic Leukemia · principal investigator
- Ph1NCT04402723 · Combination of Donafenib and Cytarabine/Daunorubicin in Relapsed AMLSuzhou Zelgen Biopharmaceuticals Co.,Ltd · terminated · Acute Myeloid Leukemia (AML) · principal investigator
- Ph1NCT04275518 · A Phase Ib Study of APG-115 Single Agent or in Combination With Azacitidine or Cytarabine in Patients With AML and MDS.Ascentage Pharma Group Inc. · unknown · Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS) · principal investigator
- Ph1NCT04230473 · A Clinical Trial of CNCT19 Cells in the Treatment of CD19 Positive Relapsed or Refractory Acute Lymphoblastic LeukemiaJuventas Cell Therapy Ltd. · completed · Relapsed or Refractory Acute Lymphoblastic Leukemia · principal investigator
- Ph1NCT03913949 · A Study to Evaluate the Safety,PK and PD of APG-2575 in Patients With Hematologic MalignanciesAscentage Pharma Group Inc. · active not recruiting · Chronic Lymphocytic Leukemia, Non Hodgkin Lymphoma · principal investigator
- Ph1NCT03560908 · Dasatinib Combined With Chemotherapy in Relapsed t(8;21) Acute Myeloid Leukemia With KIT D816 MutationInstitute of Hematology & Blood Diseases Hospital, China · withdrawn · Relapsed AML, T(8;21), C-KIT Mutation · principal investigator
- Ph1NCT03483948 · Phase I Study of HMPL-523+Azacitidine in Elderly Patients With Acute Myeloid LeukemiaHutchison Medipharma Limited · terminated · Acute Myeloid Leukemia · principal investigator
- Ph1NCT03125876 · A Phase Ib Study of CT053PTSA in Relapsed / Refractory Acute Myeloid Leukemia (AML)Sunshine Lake Pharma Co., Ltd. · terminated · Acute Myeloid Leukemia (AML) · study chair
- Ph1/Ph2NCT03031262 · Efficacy and Safety of Chidamide in CBF LeukemiaInstitute of Hematology & Blood Diseases Hospital, China · active not recruiting · AML · principal investigator
- Ph1/Ph2NCT03031249 · Efficacy and Safety of ATO Plus ATRA in Nucleophosmin-1 Mutated Acute Myeloid LeukemiaInstitute of Hematology & Blood Diseases Hospital, China · enrolling by invitation · AML · principal investigator
- Ph1/Ph2NCT03021395 · Efficacy of Decitabine in Clearance of MRDInstitute of Hematology & Blood Diseases Hospital, China · withdrawn · AML · principal investigator
- Ph3NCT03021330 · Efficacy of Intermediate-Dose Cytarabine Induction Regimen in Adult AMLInstitute of Hematology & Blood Diseases Hospital, China · active not recruiting · AML · principal investigator
- Ph1NCT02975687 · CD19 CAR T Cells in Patients With Resistant or Refractory CD19+ Acute Lymphoblastic LeukemiaInstitute of Hematology & Blood Diseases Hospital, China · completed · Acute Lymphoblastic Leukemia, Adult B-Cell, Acute Lymphoblastic Leukaemia Recurrent · principal investigator
- Ph2NCT02937662 · Efficacy of Idarubicin, Cytarabine and Cyclophosphamide (IAC) Regimen in Relapsed/Refractory AMLInstitute of Hematology & Blood Diseases Hospital, China · completed · Acute Myeloid Leukemia · principal investigator
- Ph2NCT02523976 · Dasatinib Combined With Chemotherapy in Philadelphia Chromosome-positive Acute Lymphoblastic LeukemiaInstitute of Hematology & Blood Diseases Hospital, China · completed · Acute,Leukemia, Lymphoid · principal investigator
- N/ANCT02432872 · Treatment of Older Adult Acute Myeloid Leukemia Patients Aged 55 to 65 YearsJianxiang Wang · unknown · Acute Myeloid Leukemia · principal investigator
- Ph4NCT02267993 · Efficacy and Safety of rhTPO for the Treatment of Thrombocytopenia After Chemotherapy in AML PatientsInstitute of Hematology & Blood Diseases Hospital, China · completed · Thrombocytopenia · principal investigator
- Ph3NCT01633099 · Therapeutic Effect and Safety Study of Decitabine in Elderly Acute Myeloid Leukemia PatientsJianxiang Wang · unknown · Untreated Adult Acute Myeloid Leukemia, Effect of Drugs, Drug Safety · principal investigator
- Ph2NCT01503502 · A Phase II Study of Flumatinib Versus Imatinib to Treat Philadelphia Chromosome Positive Chronic Myelogenous LeukemiaJiangsu HengRui Medicine Co., Ltd. · unknown · Myelogenous Leukemia, Chronic · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 08:12 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 08:12 UTC. The ranking covers the 200 most relevant of 5726 PubMed records, and a shared surname and initials can bring in a namesake. All 5726 on PubMed
- 131 citationsRCR 36.7
- Survival with Osimertinib plus Chemotherapy in EGFR-Mutated Advanced NSCLC.N Engl J Med · 2026107 citationsRCR 53.5
- Targeting dormant tumor cells to prevent recurrent breast cancer: a randomized phase 2 trial.Nat Med · 202538 citationsRCR 7.3
- Mosunetuzumab Plus Polatuzumab Vedotin in Transplant-Ineligible Refractory/Relapsed Large B-Cell Lymphoma: Primary Results of the Phase III SUNMO Trial.J Clin Oncol · 202538 citationsRCR 7.8
- 28 citationsRCR 14.0
- Time-of-day immunochemotherapy in non-small cell lung cancer: a randomized phase 3 trial.Nat Med · 202628 citationsRCR 14.0
- 22 citationsRCR 11.0
- 21 citationsRCR 3.7
- Long-Term Outcomes of Left Bundle-Branch Pacing vs Biventricular Pacing in Heart Failure: The HeartSync-LBBP Randomized Clinical Trial.JAMA Cardiol · 202621 citationsRCR 10.5
- Endovascular Treatment of Medium-Vessel-Occlusion Strokes.N Engl J Med · 202620 citationsRCR 10.0